# EDGAR Filing Document

**Accession Number:** 0001355736
**File Stem:** 0001493152-25-027070
**Filing Date:** 2025-12
**Character Count:** 13333
**Document Hash:** 61b0a0ec2ab559ce11e5b832e762034f
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-25-027070.hdr.sgml**: 20251210

**ACCESSION NUMBER**: 0001493152-25-027070

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 3

**CONFORMED PERIOD OF REPORT**: 20251130

**FILED AS OF DATE**: 20251210

**DATE AS OF CHANGE**: 20251210

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Avricore Health Inc.
- **CENTRAL INDEX KEY:** 0001355736
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** A1
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-51848
- **FILM NUMBER:** 251562103

**BUSINESS ADDRESS:**
- **STREET 1:** 789 WEST PENDER STREET
- **STREET 2:** SUITE 810
- **CITY:** VANCOUVER
- **STATE:** A1
- **ZIP:** V6C 1H2
- **BUSINESS PHONE:** 604-687-2038

**MAIL ADDRESS:**
- **STREET 1:** 789 WEST PENDER STREET
- **STREET 2:** SUITE 810
- **CITY:** VANCOUVER
- **STATE:** A1
- **ZIP:** V6C 1H2

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Vanc Pharmaceuticals Inc.
- **DATE OF NAME CHANGE:** 20140911

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** NUVA Pharmaceuticals Inc.
- **DATE OF NAME CHANGE:** 20140110

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ALDA Pharmaceuticals Corp.
- **DATE OF NAME CHANGE:** 20060309

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**Form 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934**

For the month of November 2025.

Commission File Number: **000-51848**

**Avricore Health Inc.**

(Exact name of registrant as specified in its charter)

1120-789 West Pender St, Vancouver, BC, V6C 1H2

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): <u>NO</u>

**Note**: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): <u>NO</u>

**Note**: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant's "home country"), or under the rules of the home country exchange on which the registrant's securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

Exhibits

The following exhibits are included in this form 6-K:

<u>Exhibit No.</u> <u>Description</u> <u>Date Released</u> <br> 1 [News Release - HealthTab to Power NHS Pilot](ex1.htm) 2025-11-27

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**AVRICORE HEALTH INC.**

Date: December 10, 2025 By <u>*"Kiki Smith"*</u> <br> Kiki Smith <br> Chief Financial Officer

---

| | |
|:---|:---|
| SEC1815(04-09) | **Persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number** |

---

## Ex-1

**Exhibit 1**

![](ex1_001.jpg)

**HealthTab™ to Power NHS Pilot**

**Bringing Cholesterol-Lowering Injections to U.K. Community Pharmacies**

VANCOUVER, BRITISH COLUMBIA – November 27, 2025) – **AVRICORE HEALTH INC.** (TSXV: AVCR) (the "**Company**" or "**Avricore**") is pleased to announce HealthTab™ is being deployed in a new pilot launched by Barts Health NHS Trust, in collaboration with UCL Partners and the British Heart Foundation (BHF), to deliver inclisiran cholesterol-lowering injections through community pharmacies.

**Key Highlights**

● **HealthTab™ enters secondary-prevention care inside the NHS** — a major expansion from screening into therapy-linked workflows.

● **Integration with Ortus-iHealth connects HealthTab directly into hospital clinical systems**, positioning the platform as core infrastructure for NHS pharmacy-based care.

● **Inclisiran pilot validates HealthTab as a trusted technology partner** inside a high-profile cardiovascular program.

● **Significantly expands HealthTab's addressable marke** t by enabling participation in long-term lipid management pathways.

● **Strengthens Avricore's position in U.K. community pharmacy networks**, aligning perfectly with NHS policy to shift chronic-condition management into pharmacies.

Supported by a £198,000 BHF grant, the pilot reflects growing momentum toward decentralizing cardiovascular therapy delivery and reducing hospital burden by shifting appropriate services into community pharmacies, while better supporting people with long-term conditions closer to home. The initiative builds on the ELoPE-CVD programme, which aims to expand access to preventive heart care in local communities and optimise lipid management for patients at highest cardiovascular risk.

**HealthTab Integration with Ortus-Health Platform**

A major advancement enabling this new pathway is the integration of HealthTab™ with the Ortus-iHealth platform, which allows pharmacy-generated results to flow directly into hospital clinical systems. This connectivity complements HealthTab's existing integration with the NHS App (via Patient Knows Best), ensuring data is instantly available to both specialist clinicians and patients within established NHS digital pathways.

**From Primary to Secondary Prevention – HealthTab's Expanding Role**

HealthTab has transformed primary prevention by making early cardiometabolic testing fast, reliable and accessible in pharmacies. This pilot now brings HealthTab into secondary prevention, enabling community pharmacies to safely deliver and monitor advanced lipid-lowering therapy for patients already living with cardiovascular disease. This is a major expansion of the platform's role, placing HealthTab at the heart of pharmacy-based treatment delivery (initiation, administration, monitoring).

"Bringing inclisiran injections into community pharmacies is an important milestone for cardiovascular care, and we're proud that HealthTab is helping make it possible," said Rodger Seccombe, CEO of Avricore Health. "We started by empowering pharmacies to identify risk through point-of-care testing. Now, by integrating with the Ortus platform and linking into specialist teams, HealthTab is enabling those same pharmacies to play a meaningful role in secondary prevention and long-term condition management."

![](ex1_001.jpg)

**HealthTab™ Supporting Pharmacy-Led Delivery of Inclisiran**

The pilot will evaluate how community pharmacies can:

● Administer inclisiran injections traditionally delivered in hospital lipid clinics

● Initiate therapy sooner for patients awaiting specialist care

● Provide structured follow-up and monitoring as part of an integrated, long-term lipid management pathway

The NHS has set out a clear ambition to prevent up to 150,000 heart attacks, strokes and cases of dementia over the next decade by improving detection and management of high-risk conditions including high cholesterol. They also commit to increasing the role of community pharmacies in the management of long-term conditions and linking them more tightly into shared digital records.

**A Major Step Forward in Platform Expansion**

**Strengthens HealthTab's Position Inside NHS Clinical Pathways**

● Being deployed within a major cardiovascular programme highlights HealthTab's role as a trusted platform for community-based diagnostics and workflow support, spanning both primary and secondary prevention.

**Integration With Ortus Enhances Platform Value**

● Connecting HealthTab™ to hospital clinical systems through Ortus moves the platform beyond diagnostics into fully integrated care-team support, helping to create the kind of interoperable, shared record infrastructure envisioned in the NHS' 10-year agenda.

**Supports Expansion Into Treatment-Linked Workflows**

● The ability to support therapy initiation, administration and monitoring, in addition to screening and testing, expands HealthTab's relevance and value for each deployed site and positions community pharmacies as key partners in long-term cardiovascular condition management.

**HealthTab™ at the Core of Scalable, Integrated POCT**

HealthTab™ is a complete, turnkey solution for community-based POCT networks, combining best-in-class instruments, cloud software, standardized workflows, and comprehensive training and support. At its center is a secure, cloud-based platform that seamlessly connects point-of-care analyzers, patient results, and QC data into a unified digital infrastructure for distributed testing environments.

This fully integrated approach ensures quality-assured testing, consistent data capture across all locations, and real-time analytics for public-health reporting and performance monitoring, while dramatically reducing implementation complexity for participating sites.

**Commitment to Quality and Accuracy**

HealthTab™ is designed to meet the highest standards of analytical performance and reliability. Through its partnership with CEQAL Inc., a world-leading reference method laboratory and member of the CDC Cholesterol Reference Method Laboratory Network (CRMLN), HealthTab operates a comprehensive quality management program that mirrors the rigour of accredited clinical laboratories.

The program includes centralized lot monitoring of reagents, internal quality-control procedures, regular external quality-assessment (EQA) events, and expert oversight services to support the accuracy, consistency, and traceability of results to internationally recognized reference standards across participating sites.

![](ex1_001.jpg)

**About Avricore Health Inc.**

Avricore Health Inc. (TSXV: AVCR) is a pharmacy service innovator focused on acquiring and developing early-stage technologies aimed at advancing pharmacy practice and patient care. Through its flagship offering HealthTab™, a wholly owned subsidiary, the Company's mission is to make actionable health information more accessible to everyone by creating the world's largest network of rapid testing devices in community pharmacies.

**Contact:**

Avricore Health Inc.

<u>info@avricorehealth.com</u>

<u>avricore.com</u>

**Cautionary Note Regarding Forward-Looking Statements**

Information in this press release that involves Avricore Health's expectations, plans, intentions, or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. Avricore Health generally uses words such as "outlook," "will," "could," "would," "might," "remains," "to be," "plans," "believes," "may," "expects," "intends," "anticipates," "estimate," "future," "positioned," "potential," "project," "remain," "scheduled," "set to," "subject to," "upcoming," and similar expressions to help identify forward-looking statements. In this press release, forward-looking statements include statements regarding: the completion of the placement and the expected timing thereof and the Company's expected use of proceeds from the placement; the unique features that the HealthTab™ platform offers to pharmacists and patients. Forward-looking statements reflect the then-current expectations, beliefs, assumptions, estimates and forecasts of Avricore Health's management. The forward-looking statements in this press release are based upon information available to Avricore Health as of the date of this press release. Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of Avricore Health and are subject to a few risks, uncertainties, and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations, including without limitation: failure to meet regulatory requirements; changes in the market; potential downturns in economic conditions; and other risk factors described in Avricore's public filings. These forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances, unless otherwise required to do so by law.

*Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news report.*